Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Will FDA Order Uloric Recall Requested In June 2018 By Public Citizen

July 13, 2018 By Law Offices of Thomas J. Lamb, P.A.

The consumer advocacy group Public Citizen asserts that a FDA Uloric recall is necessary following results of a large postmarketing study that showed higher rates of fatal cardiovascular (CV) events and all-cause mortality in patients taking the drug. More exactly, it is the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidity (CARES) clinical trial results which are pointed out by a June 21, 2018 Public Citizen petition letter sent to the FDA.

Details about this Uloric recall request submitted to the FDA are set forth in Public Citizen’s June 21, 2018 Citizen Petition. Here are two such excerpts:

(1) On November 15, 2017, the FDA issued a drug safety communication alerting the public that preliminary results from the FDA-mandated post-market randomized controlled trial to assess the safety of [Uloric (febuxostat)] showed an increased risk of cardiovascular-related death and all-cause death with [Uloric (febuxostat)] compared with allopurinol. The agency recommended that “[h]ealth care professionals should consider this safety information when deciding whether to prescribe or continue patients on [Uloric (febuxostat)].”

On March 12, 2018, White et al. published the results of the postmarket clinical trial in The New England Journal of Medicine online, which demonstrated non-inferiority in terms of the primary composite cardiovascular outcomes endpoint but higher all-cause and cardiovascular mortality in [Uloric (febuxostat)]-exposed subjects than in allopurinol-exposed subjects. [footnotes omitted]

(2) The results of the FDA-mandated postmarket trial now provide additional high-quality evidence of a causal link between treatment with [Uloric (febuxostat)] and increased risk of all-cause death and cardiovascular death. The FDA almost certainly would have denied approval of [Uloric (febuxostat)] if data from this postmarket trial had been available at the time of the initial NDA submission, and the appropriate course of action now is obvious. We therefore request that the FDA remove from the market all medications containing [Uloric (febuxostat)].

Uloric was initially approved by the FDA in 2009.

Our law firm is currently investigating possible Uloric drug injury lawsuits against Takeda for which we are offering free case evaluations for patients and their family.

[View article at original source]

Uloric

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: card, Cardiovascular death, drug side effects, FDA, Uloric

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.